Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/csl-ltd" target="_blank" data-smartkarma-citation="entities:917:1" rel="noopener">CSL Ltd (CSL AU)</a> announced FY26 result, reporting revenue of $15.8B, down 1% YoY. After one-off restructuring costs and impairments, the company reported a net loss of $2.6B.   </li>
<li>In FY27, CSL expects underlying NPAT growth of 5% on flat revenue. NPAT outlook exceeds market consensus expectations, thereby cementing CSL’s core operational rebound.</li>
<li>Despite CSL Vifor headwinds (revenue decline of 25% YoY mainly due to generic competition in iron products), Behring and Seqirus are expected to return to growth path.</li>
</ul>



CSL Ltd (CSL AU) announced FY26 result, reporting revenue of $15.8B, down 1% YoY. After one-off restructuring costs and impairments, the company reported a net loss of $2.6B.   
In FY27, CSL expects underlying NPAT growth of 5% on flat revenue. NPAT outlook exceeds market consensus expectations, thereby cementing CSL’s core operational rebound.
Despite CSL Vifor headwinds (revenue decline of 25% YoY mainly due to generic competition in iron products), Behring and Seqirus are expected to return to growth path.


CSL Ltd (CSL AU): Initial Sign of Recovery or a Dead Cat Bounce?

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>CSL is a global biotechnology leader with a dominant position in the plasma-derived therapies market, a significant presence in the influenza vaccine sector, and a growing franchise in iron deficiency and nephrology treatments.</li>
 <li>The company's primary competitive advantage stems from its vast, vertically integrated plasma collection network, which creates significant barriers to entry and provides a cost advantage over competitors.</li>
 <li>Recent earnings downgrades, challenges in the immunoglobulin and albumin markets, and concerns over management execution have led to a significant de-rating of the stock, creating uncertainty despite a healthy long-term demand outlook for its core products.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  CSL is a global biotechnology leader with a dominant position in the plasma-derived therapies market, a significant presence in the influenza vaccine sector, and a growing franchise in iron deficiency and nephrology treatments.
  The company's primary competitive advantage stems from its vast, vertically integrated plasma collection network, which creates significant barriers to entry and provides a cost advantage over competitors.
  Recent earnings downgrades, challenges in the immunoglobulin and albumin markets, and concerns over management execution have led to a significant de-rating of the stock, creating uncertainty despite a healthy long-term demand outlook for its core products.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 28th September, published on the 2nd October.
</li>
<li>The largest industry net increase in the past week was A$0.4bn into "Banks"; the largest industry net decrease was A$0.1bn out of "Interactive Media". Net shorts increased A$0.5bn week-on-week. 
</li>
<li>Companies mentioned in this regular weekly report include: <a href="https://www.smartkarma.com/entities/bhp-group-ltd" target="_blank" data-smartkarma-citation="entities:147:1" rel="noopener">BHP Group (BHP AU)</a>, <a href="https://www.smartkarma.com/entities/steadfast-group-ltd" target="_blank" data-smartkarma-citation="entities:8181:1" rel="noopener">Steadfast (SDF AU)</a>, <a href="https://www.smartkarma.com/entities/artrya-ltd" target="_blank" data-smartkarma-citation="entities:41151:1" rel="noopener">Artrya (AYA AU)</a>, <a href="https://www.smartkarma.com/entities/echoiq-limited" target="_blank" data-smartkarma-citation="entities:8230:1" rel="noopener">ECHOiQ (EIQ AU)</a>, <a href="https://www.smartkarma.com/entities/catalyst-metals-ltd" target="_blank" data-smartkarma-citation="entities:4293:1" rel="noopener">Catalyst Metals (CYL AU)</a>, and <a href="https://www.smartkarma.com/entities/core-lithium-ltd" target="_blank" data-smartkarma-citation="entities:14712:1" rel="noopener">Core Lithium (CXO AU)</a>.</li>
</ul>


Australia's ASIC releases the aggregated short position data four business days after the reporting day. Data in this insight is up to 28th September, published on the 2nd October.

The largest industry net increase in the past week was A$0.4bn into "Banks"; the largest industry net decrease was A$0.1bn out of "Interactive Media". Net shorts increased A$0.5bn week-on-week. 

Companies mentioned in this regular weekly report include: BHP Group (BHP AU), Steadfast (SDF AU), Artrya (AYA AU), ECHOiQ (EIQ AU), Catalyst Metals (CYL AU), and Core Lithium (CXO AU).


Aussie Shorts [28 Sep 2026]: BHP Group, Steadfast, Artrya, ECHOiQ, Catalyst Metals, Core Lithium

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

<ul><li>CSL surprised even the most cautious commentators with (yet again) a hefty downgrade for future earnings.</li><li>Analysts are questioning where to now?</li><li> Weakness in immunoglobulin and albumin drives another major earnings reset Analysts question whether CSL&rsquo;s Behring challenges are cyclical or structural Competition, pricing pressure and NHS contract loss weigh on outlook CSL&rsquo;s valuation premium has evaporated amid ongoing downgrades</li></ul>

CSL surprised even the most cautious commentators with (yet again) a hefty downgrade for future earnings.Analysts are questioning where to now? Weakness in immunoglobulin and albumin drives another major earnings reset Analysts question whether CSL&rsquo;s Behring challenges are cyclical or structural Competition, pricing pressure and NHS contract loss weigh on outlook CSL&rsquo;s valuation premium has evaporated amid ongoing downgrades

CSL Challenges Pile On, Where's The Upside?

<ul>
 <li>
<a href="https://smartkarma.com/entities/csl-ltd-da4ff9e1-4f32-4e1d-9b0e-e922da636493">CSL </a>is a global biotechnology leader with a dominant position in plasma-derived therapies (<a href="https://smartkarma.com/entities/csl-ltd-da4ff9e1-4f32-4e1d-9b0e-e922da636493">CSL </a>Behring) and a significant presence in the influenza vaccine market (<a href="https://smartkarma.com/entities/csl-ltd-da4ff9e1-4f32-4e1d-9b0e-e922da636493">CSL </a>Seqirus).</li>
 <li>The recent acquisition of Vifor Pharma has diversified CSL's portfolio into the attractive markets of nephrology and iron deficiency, providing a new avenue for growth.</li>
 <li>While facing near-term headwinds from policy changes, competitive pressures, and a recent CEO transition, the company's long-term outlook is supported by a strong R&amp;D pipeline, recovering plasma collections, and strategic cost-saving initiatives.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
CSL is a global biotechnology leader with a dominant position in plasma-derived therapies (CSL Behring) and a significant presence in the influenza vaccine market (CSL Seqirus).
  The recent acquisition of Vifor Pharma has diversified CSL's portfolio into the attractive markets of nephrology and iron deficiency, providing a new avenue for growth.
  While facing near-term headwinds from policy changes, competitive pressures, and a recent CEO transition, the company's long-term outlook is supported by a strong R&amp;D pipeline, recovering plasma collections, and strategic cost-saving initiatives.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Australia

CSL Limited develops, manufactures and markets human pharmaceutical and diagnostic products derived from human plasma. The Company's products include pediatric and adult vaccines, infection, pain medicine, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CSL Ltd (CSL AU)

CSL Ltd (CSL AU): Initial Sign of Recovery or a Dead Cat Bounce?

CSL announced FY26 result, in-line with updated guidance. The company expects 5% NPAT growth on flat revenue in FY27, thereby cementing operational...

Tina Banerjee

Primer: CSL Ltd (CSL AU) - Aug 2026

CSL is a global biotechnology leader with a dominant position in the plasma-derived therapies market, a significant presence in the influenza...

αSK Primers

Aussie Shorts [28 Sep 2026]: BHP Group, Steadfast, Artrya, ECHOiQ, Catalyst Metals, Core Lithium

The largest industry net increase in the past week was A$0.4bn into "Banks"; the largest industry net decrease was A$0.1bn out of "Interactive...

David Blennerhassett

CSL Challenges Pile On, Where's The Upside?

CSL surprised even the most cautious commentators with (yet again) a hefty downgrade for future earnings. Analysts are questioning where to...

FNArena

Primer: CSL (CSL AT) - Feb 2026

CSL is a global biotechnology leader with a dominant position in plasma-derived therapies (CSL Behring) and a significant presence in the...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)